|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The next generation sequencing (NGS) informatics market was valued at approximately USD 2,250 million in 2020 and is expected to witness a revenue of USD 5,750 million in 2026, with a CAGR of 19% over the forecast period (2021-2026).
The NGS informatics market is expected to peak during the current COVID-19 pandemic. Next generation sequencing is considered a valuable tool in the characterization and identification of the SARS-CoV2 virus. Though qPCR is extensively used in the detection and quantification of coronavirus in the pandemic, the major disadvantage is that qPCR is unable to decipher accurate changes or mutations in the viral genome. Thus, NDS technologies play a vital role in studying the mutations in the viral genome and their impact on human health. According to a research article published in Clinical OMICS, 2020, approximately 84,000 viral genomic sequences of the coronavirus have been uploaded to the Global Initiative to Share All Influenza Data (GISAID) as of August 2020, and the analysis of 4,641 genomes revealed that the virus continues to mutate as it spreads, with one or two base changes per month. In this context, NGS plays a vital role in studying the evolving process of the SARS-CoV2 virus and the subsequent impact of these changes on the global population and environmental health, along with tracking the transmission of the virus globally. Thus, given the aforementioned factors, the COVID-19 pandemic is expected to impact the studied market significantly.
Additionally, the major factors driving the growth of the next-generation sequencing informatics market are the increasing clinical applications of NGS, technological advancements in NGS informatics tools, growing preference toward personalized medicines and early disease diagnosis, along with the increasing demand for NGS services and investments by key players. Applications include whole-genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses. There are various technological advancements in the field of medicine that are growing at a rapid pace and have led to the development of personalized medicines. There are a huge number of applications of next-generation sequencing in personalized medicine. Thus, the development of personalized medicine has opened up many avenues for the application of NGS, which could accelerate the market growth. When compared to Sanger sequencing, NGS has emerged as the dominant genomics technology because of its cost effectiveness and has been in use in a wide range of functional genomics applications, from sequencing a group of candidate genes, all coding regions (known as exome sequencing) to the entire human genome. Thus, the wide range of applications of NGS technology in turn increases the demand for NGS informatics, which in turn aids in the growth of the studied market over the forecast period.
However, the unavailability of skilled professionals for the analysis and interpretation of NGS data, along with the lack of knowledge of new informatics tools among medical professionals, is likely to limit the growth of the market studied. Additionally, the high cost involved in the maintenance and security of informatics tools is likely to contribute to the limitation.
Scope of the Report
The NGS informatics market (henceforth referred to as the market studied) includes various types of sequencing services, which fuel the introduction of new methods that provide great opportunities for low-cost and fast DNA sequencing. This market is segmented by product and services, application, end user, and geography. By product and services, the market is segmented into NGS informatics services, data analysis and management tools, and primary and secondary data analysis tools. By application, the market is segmented into drug discovery, genetic screening, precision medicine, and other applications. By end user, the market is segmented into hospitals and clinics, academics and research institutes, pharmaceutical companies, and others. By geography, the market is segmented into North America, Europe, Asia-pacific, the Middle East and Africa, and South America. The report offers the value (in USD million) for the above segments.
|By Products and Services|
|NGS Informatics Services|
|Primary and Secondary Data Analysis Tools|
|By End User|
|Hospitals and Clinics|
|Academics and Research Institutes|
|Other End Users|
Key Market Trends
Genetic Screening Segment, by Application, is Expected to Experience the Fastest Growth in the Market
In genetic screening, the NGS technology is highly useful in identifying monogenic diseases with locus heterogeneity, such as blindness, deafness, movement disorders, mitochondrial disease, hereditary cancers, etc. It generates a large amount of sequencing data in a massively parallel manner, in order to provide a differential diagnosis for the patient. There are several companies in the market that provide NGS services for a range of genetic disorders and screening of DNA, RNA, and specialized samples. There is a high scope for technological improvement in the application of NGS in genetic testing. According to the research article published in Trends in Genetics, 2019, the next-generation sequencing technologies have remarkable potential in the genetic testing and diagnosis of rare genetic disorders. NGS technologies are expected to be highly useful in clinical settings to identify specific causal mutations in the DNA sequence. According to the Rare Disease day, rare diseases are estimated to affect nearly 3.5% - 5.9% of the global population in 2020 with over 300 million people living with one or more of over 6,000 identified rare diseases around the world. Thus, the high incidence of rare diseases pushes the demand for genetic screening, and NGS technologies have promising results in genetic screening. Additionally, NGS technologies have been extensively harnessed in oncology screening and the high incidence of cancers worldwide is expected to drive the studied market.
Additionally, the growing NGS platform launches are also driving the market growth. For instance, in August 2020, Quest Diagnostics launched the Automated NGS engine to aid in faster and cost-effective genetic screening. The increasing NGS product launches raise the demand for subsequent bioinformatics and thus, the aforementioned factors are expected to drive the growth of the studied market over the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to do Similar Over the Forecast Period
North America is expected to dominate the overall market throughout the forecast period. The presence of high per capita healthcare expenditure, coupled with high patient awareness levels and high prevalence of target diseases, is contributing to the growth of the market studied in the region. In the North American region, the United States holds the largest market share. According to the GLOBOCON 2020, 2,281,658 new cancer cases were diagnosed in the United States in 2020, with 612,390 deaths. Among all types of cancers, breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809). The increasing incidence of chronic diseases is expected to drive the need for next-generation sequencing panels, which in turn will likely surge the studied market growth. Also, various government bodies, like NHGRI (National Human Genome Research Institute, United States), have been supporting research related to human genome sequencing, while funding research related to the genome's structure, function, and role in health and disease. Moreover, these organizations support studies on ethical, legal, and social implications (ELSI) of genome research.
Additionally, the high concentration of major players in the region, along with high product approval and launches, is expected to be the major factor for the growth of the studied market in the region. For instance, in July 2019, Abbott launched a laboratory information management system, STARLIMS Life Sciences Solution 11.1, to help manage complex sample and testing workflows in pre-clinical, clinical research, biorepository, animal health, molecular, specialty diagnostics, and academic research. Thus, given the aforementioned factors, the NGS informatics market is expected to grow over the forecast period in North America.
To understand geography trends, Download Sample Report
The next-generation sequencing informatics market is consolidated and consists of a few major players. In terms of market share, few of the major players currently dominate the market. With rising patient awareness levels and the high prevalence of target diseases, few other smaller players are expected to enter the market. Some of the major players of the market are Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Intrexon Bioinformatics Germany GmbH, and Illumina Inc., among others. Most of these companies are involved in strategic alliances, such as acquisitions, research, and development activities, along with new product launches, to expand the product portfolio globally. For instance, in January 2020, Illumina Inc entered into a 15-year non-exclusive collaboration agreement with Roche, and the launch of TruSight Software Suite v1.0 to accelerate adoption of genomics.
In October 2020, Fabric Genomics launched Fabric GEM Algorithm, which uses advanced artificial intelligence (AI) to automate rare disease diagnostics from next-generation sequencing data.
In June 2020, DNAnexus raised USD 100 million for a cloud-based analytics platform to be used in genomics and other clinical Big Data.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Clinical Applications of NGS
4.2.2 Technological Advancements in NGS Informatics Tools
4.2.3 Growing Preference toward Personalized Medicines and Early Disease Diagnosis
4.2.4 Increasing Demand for NGS Services and Rising Investment by Key Players
4.3 Market Restraints
4.3.1 Lack of Skilled Technicians for NGS Informatics Services
4.3.2 Challenges Associated with Data Storage and Integration
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Products and Services
5.1.1 NGS Informatics Services
5.1.2 Data Analysis and Management Tool
188.8.131.52 Storage and Computing Tool
184.108.40.206 Laboratory Information Management System (LIMS)
220.127.116.11 Data Interpretation and Reporting Tools
5.1.3 Primary and Secondary Data Analysis Tools
5.2 By Application
5.2.1 Drug Discovery
5.2.2 Genetic Screening
5.2.3 Precision Medicine
5.2.4 Other Applications
5.3 By End User
5.3.1 Hospitals and Clinics
5.3.2 Academics and Research Institutes
5.3.3 Pharmaceuticals Companies
5.3.4 Other End Users
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-pacific
5.4.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Dnanexus Inc.
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Intrexon Bioinformatics Germany GmbH (Genomatix AG)
6.1.5 llumina Inc.
6.1.6 Fabric Genomics Inc. (Omicia Inc.)
6.1.7 Partek Incorporated
6.1.8 Qiagen NV
6.1.9 Sapio Sciences
6.1.10 Thermo Fischer Scientific Inc.
6.1.11 DNASTAR Inc.
6.1.12 PerkinElmer, Inc
6.1.13 BIOVIA(Dassault Systemes)
6.1.14 IBM Corporation
6.1.15 GENEWIZ, Inc.
6.1.16 Eagle Genomics Ltd
6.1.17 Real Time Genomics Inc.
6.1.18 SoftGenetics, LLC
6.1.19 PierianDx, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Next-Generation Sequencing Informatics Market market is studied from 2018 - 2026.
What is the growth rate of Global Next-Generation Sequencing Informatics Market?
The Global Next-Generation Sequencing Informatics Market is growing at a CAGR of 19% over the next 5 years.
Which region has highest growth rate in Global Next-Generation Sequencing Informatics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Next-Generation Sequencing Informatics Market?
North America holds highest share in 2021.
Who are the key players in Global Next-Generation Sequencing Informatics Market?
Intrexon Bioinformatics Germany GmbH, Illumina Inc., DNASTAR Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd. are the major companies operating in Global Next-Generation Sequencing Informatics Market.